2018
Continued Interest and Controversy: Vitamin D in HIV
Hsieh E, Yin MT. Continued Interest and Controversy: Vitamin D in HIV. Current HIV/AIDS Reports 2018, 15: 199-211. PMID: 29713871, PMCID: PMC6003869, DOI: 10.1007/s11904-018-0401-4.BooksConceptsVitD deficiencyVitD supplementationExtra-skeletal outcomesSetting of HIVSubgroup of HIVBone mineral densityRecent FindingsRecent studiesART regimensD deficiencyClinical outcomesPoor outcomeSummaryFurther researchVitamin DChronic diseasesClinical trialsDifferent demographic strataMineral densityClinical roleHIVGreater riskDemographic strataSignificant heterogeneityOutcomesRiskSupplementation
2016
Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV
Hsieh E, Fraenkel L, Han Y, Xia W, Insogna KL, Yin MT, Zhu T, Cheng X, Li T. Longitudinal increase in vitamin D binding protein levels after initiation of tenofovir/lamivudine/efavirenz among individuals with HIV. AIDS 2016, 30: 1935-1942. PMID: 27124896, PMCID: PMC4949136, DOI: 10.1097/qad.0000000000001131.Peer-Reviewed Original ResearchConceptsTenofovir disoproxil fumarateVitamin DProcollagen type 1 N-terminal propeptideInitiation of TDFTenofovir/lamivudine/efavirenzVitamin D binding protein (VDBP) levelsCollagen type 1 cross-linked C-telopeptideIntact parathyroid hormone levelsCross-linked C-telopeptideIntact parathyroid hormoneParathyroid hormone levelsTotal procollagen type 1 N-terminal propeptideBinding protein levelsProtein levelsMulticenter clinical trialPlasma samplesOngoing multicenter clinical trialsN-terminal propeptideClinical characteristicsParathyroid hormoneBone lossFormation markersDisoproxil fumarateC-telopeptideBone resorption